Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484307 | 1.00 | HTR2C (0.56) | HTR2CGAATDP1HCRTR2CHRM5 | |
| SCHEMBL29589456 | 1.00 | HTR2C (0.56) | HTR2CGAATDP1HCRTR2CHRM5 | |
| Hydrochloric Acid SCHEMBL31444282 | 0.98 | HTR2C (0.57) | HTR2CGAATDP1HCRTR2CHRM5 | |
| Hydrochloric Acid SCHEMBL6092900 | 0.98 | HTR2C (0.57) | HTR2CGAATDP1HCRTR2CHRM5 | |
| SCHEMBL30092853 | 0.95 | HTR2C (0.54) | HTR2CGAATDP1HCRTR2HTR2B | |
| SCHEMBL30092890 | 0.87 | HTR2C (0.61) | HTR2CGAATDP1HTR2BSLC6A2 | |
| SCHEMBL23323083 | 0.87 | HTR2C (0.41) | HTR2CHCRTR2CHRM5CHRM3CHRM1 | |
| SCHEMBL28946603 | 0.87 | HTR2C (0.41) | HTR2CGAAHCRTR2CHRM5CHRM3 | |
| SCHEMBL28946600 | 0.87 | HTR2C (0.41) | HTR2CGAAHCRTR2CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL5251755 | 0.84 | POLB (0.56) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-11420968-B2 | Bcl-2 inhibitors | BEIGENE, LTD. (KY) | 2022-08-23 | — | — | US | disclosed |
| WO-2021223736-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-11-11 | — | — | WO | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| WO-2014151936-A9 | OCTAHYDROPYRROLOPYRROLES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014151936-A1 | OCTAHYDROPYRROLOPYRROLES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2678338-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-12-12 | — | — | US | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012034095-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012034095-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | HTR2C 3764/4885GAA 1765/4885TDP1 2551/4885 |
| US-11420968-B2 | Bcl-2 inhibitors | BCL2, BCL2L1, BCL2L2 | HTR2C 3764/4885GAA 1765/4885TDP1 2551/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | HTR2C 3764/4885GAA 1765/4885TDP1 2551/4885 |
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | CNKSR1, BMP2K, RAF1 | HTR2C 3729/4885GAA 3104/4885TDP1 937/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | HTR2C 3764/4885GAA 1765/4885TDP1 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.